Zai Lab

ZLABPhase 3

Shanghai and Cambridge, ChinaFounded 2014zailaboratory.com

Founded in 2014 by Dr. Samantha Du, Zai Lab has grown into a leading global biopharma with a dual headquarters in China and the U.S. The company combines in-licensed assets with strategic partnerships and internal R&D to build a robust pipeline, with eight products already on the market in China. Its mission is to bridge gaps in global health by advancing breakthrough therapies for patients with significant unmet medical needs.

Market Cap

$2.0B

Founded

2014

Focus

Small Molecules

ZLAB · Stock Price

USD 18.0924.22 (-57.24%)

Historical price data

AI Company Overview

Technology Platform

Zai Lab's core strength is its fully integrated biopharma operational platform, combining strategic in-licensing/partnerships with internal R&D focused on novel modalities like ADCs and bispecific antibodies to develop and commercialize therapies from discovery to market.

Pipeline Snapshot

36 drugs in pipeline, 8 in Phase 3

Drug	Indication	Stage
ZL-2306(nirapairb) + Placebo	Extensive-stage Small Cell Lung Cancer	Phase 3
Xanomeline and Trospium Chloride Capsules + Placebo	Schizophrenia	Phase 3
ZL-2306(nirapairb) + Placebos	Platinum-sensitive Relapsed Ovarian Cancer	Phase 3
ZL-1109 (VRDN-003) + Placebo	Thyroid Eye Disease (TED)	Phase 3
Omadacycline + Moxifloxacin	Community-acquired Bacterial Pneumonia	Phase 3

Funding History

Total raised: $1.1B

Follow-on Offering$750MMorgan StanleyFeb 15, 2021

IPO$173MMorgan StanleySep 15, 2017

Series B$100MKleiner PerkinsJan 15, 2016

Series A$30MKleiner PerkinsJan 15, 2014

Opportunities

Zai Lab's primary growth opportunities lie in successfully advancing its internal pipeline (especially zocilurtatug pelitecan) to global markets, capturing a larger share of China's fast-growing innovative drug market with its commercial portfolio, and leveraging its reputation to secure additional high-value partnership deals for both China and global rights.

Risk Factors

Key risks include clinical failure of its lead internal assets, intense competition in its core therapeutic areas, regulatory hurdles in both China and the U.S., geopolitical tensions impacting operations, and dependency on the success of partnered programs for near-term revenue.

Competitive Landscape

Zai Lab competes with large global pharma and biotech companies in oncology (e.g., Amgen, AstraZeneca, Gilead) and immunology (e.g., Sanofi, Regeneron). Its differentiation stems from its unique integrated China/global operational model, strategic partnering capability, and a focused internal R&D effort on novel mechanisms like DLL3 and LRRC15.

Publications

Pipeline